Future of Pfizer stock

Hey guys,

what is the major takeaway on Pfizer stock? Time to sell or hold? Are they going to get vaxx approved for infants and booster every 6 months or going down with veritas videos exposing all the shit going on inside of the company?

2 Comments
 
Most Helpful

Project Veritas is not a credible source. You need only look at the ACORN debacle to figure that one out (their tactics ultimately resulted in the closure of ACORN). They selectively edit tape recordings to suit their own propaganda purposes, like they did in the Schiller/NPR tape that made it seem like they didn't want federal funding.

The allegations against Pfizer are more or less that they're gagging their scientists from talking about the efficacy of natural immunity against COVID-19, which to some extent is possibly true. It isn't in the company's best interest to discuss natural immunity when they can sell vaccines and booster vaccines to governments. With that being said, there are plenty of people across the glove who do not have natural immunity, so it stands to reason that they could make use of the immunity conferred by a Pfizer vaccine.

Even in the COVID crash, Pfizer stock had its lowest close on Mar. 20, 2020 with $27.48, which is 34.6% lower than prevailing market prices at time of writing. There was a lot of crap going down back then, and the stock price wasn't that far off from where it is. Much of the rest of the world is still unvaccinated, which leaves plenty of market potential even if boosters get disparaged. 

 

Tenetur ea sunt ut in et. In sint similique laboriosam harum. Et non at voluptas quo est. Id fugiat soluta laboriosam reiciendis temporibus sed illo. Minus ut ex blanditiis itaque sed. Nesciunt tempore numquam ullam. Et sed laudantium ipsum.

Qui dolore tempora enim cupiditate aperiam voluptas. Dolorem ea fugiat distinctio quo eos. Velit aut provident quisquam fugit. Quos tempora ducimus eius ducimus quo voluptates provident labore.

Qui quidem voluptatum vel delectus. Ut a sed distinctio. Voluptatum rerum perferendis optio doloribus reiciendis.

Career Advancement Opportunities

October 2026 Investment Banking

  • Evercore 01 99.5%
  • Moelis & Company 01 99.0%
  • JPMorgan 01 98.4%
  • Guggenheim Partners 02 97.9%
  • Morgan Stanley 06 97.4%

Overall Employee Satisfaction

October 2026 Investment Banking

  • Moelis & Company No 99.5%
  • Morgan Stanley 02 99.0%
  • Evercore 01 98.4%
  • Banco Santander 02 97.9%
  • BMO Capital Markets 12 97.4%

Professional Growth Opportunities

October 2026 Investment Banking

  • Evercore 01 99.5%
  • Moelis & Company 01 99.0%
  • Morgan Stanley 05 98.4%
  • Goldman Sachs 01 97.9%
  • JPMorgan No 97.4%

Total Avg Compensation

October 2026 Investment Banking

  • Vice President (16) $429
  • Associates (57) $264
  • 3rd+ Year Analyst (8) $210
  • 2nd Year Analyst (28) $184
  • Intern/Summer Associate (16) $161
  • 1st Year Analyst (84) $151
  • Intern/Summer Analyst (76) $101
notes
16 IB Interviews Notes

“... there’s no excuse to not take advantage of the resources out there available to you. Best value for your $ are the...”

Leaderboard

1
redever's picture
redever
99.2
2
BankonBanking's picture
BankonBanking
99.0
3
kanon's picture
kanon
99.0
4
Secyh62's picture
Secyh62
99.0
5
Betsy Massar's picture
Betsy Massar
98.9
6
CompBanker's picture
CompBanker
98.9
7
GameTheory's picture
GameTheory
98.9
8
dosk17's picture
dosk17
98.9
9
DrApeman's picture
DrApeman
98.9
10
Mimbs's picture
Mimbs
98.8
success
From 10 rejections to 1 dream investment banking internship

“... I believe it was the single biggest reason why I ended up with an offer...”